Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: DiaGenic Names de Potocki as CEO

Premium

DiaGenic has named Paul de Potocki as president and CEO, effective in September.

De Potocki will succeed Henrik Lund, who had been DiaGenic's interim CEO since April. He most recently served as CEO of Aerocrine. He has also served as senior vice president of commercial and strategic development at Biovitrium; and executive vice president of strategic marketing at Fresenius Kabi.

Oslo-based DiaGenic has developed technology to identify gene expression signatures in peripheral blood and the company is focused on developing biomarkers in the field of Alzheimer’s and Parkinson’s diseases. DiaGenic’s Alzheimer’s disease development program includes the CE-marked diagnostic test ADtect for detection of mild to moderate Alzheimer’s disease, and MCItect, which is under development for identifying patients with very early stages of Alzheimer’s disease.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.